Cellectis (NASDAQ:CLLS) Share Price Crosses Above Fifty Day Moving Average – What’s Next?

Cellectis S.A. (NASDAQ:CLLS) shares crossed above its 50 day moving average during trading on Monday . The stock has a 50 day moving average of $3.70 and traded as high as $3.98. Cellectis shares last traded at $3.85, with a volume of 13,554 shares.

Analysts Set New Price Targets

Several equities analysts recently weighed in on CLLS shares. Jefferies Financial Group started coverage on shares of Cellectis in a research note on Tuesday, February 17th. They issued a “buy” rating and a $7.00 target price for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Cellectis in a research note on Monday, April 20th. Finally, Citizens Jmp reissued a “market outperform” rating and issued a $8.00 target price on shares of Cellectis in a research note on Tuesday, April 14th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $6.75.

Cellectis Stock Performance

The company has a debt-to-equity ratio of 1.13, a current ratio of 1.52 and a quick ratio of 1.52. The stock’s 50-day simple moving average is $3.70 and its 200 day simple moving average is $4.02. The stock has a market capitalization of $386.31 million, a P/E ratio of -5.75 and a beta of 2.94.

Cellectis (NASDAQ:CLLS) last released its quarterly earnings data on Monday, May 11th. The biotechnology company reported ($0.18) EPS for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.08. Cellectis had a negative net margin of 89.51% and a negative return on equity of 80.66%. The firm had revenue of $7.55 million during the quarter, compared to analysts’ expectations of $11.04 million.

Institutional Investors Weigh In On Cellectis

A number of hedge funds and other institutional investors have recently modified their holdings of CLLS. Lido Advisors LLC acquired a new stake in shares of Cellectis during the first quarter worth $32,000. Global Retirement Partners LLC acquired a new stake in shares of Cellectis during the fourth quarter worth $34,000. Acadian Asset Management LLC lifted its holdings in shares of Cellectis by 132.9% during the first quarter. Acadian Asset Management LLC now owns 46,377 shares of the biotechnology company’s stock worth $55,000 after buying an additional 26,461 shares in the last quarter. Delaney Dennis R acquired a new stake in shares of Cellectis during the third quarter worth $68,000. Finally, Virtu Financial LLC acquired a new stake in shares of Cellectis during the third quarter worth $72,000. Institutional investors and hedge funds own 63.90% of the company’s stock.

Cellectis Company Profile

Cellectis is a clinical?stage biopharmaceutical company specializing in the development of gene?edited cell therapies for oncology. Founded in 1999 and headquartered in Paris, France, the company also maintains operations in New York City and Raleigh, North Carolina. Cellectis applies its proprietary TALEN genome editing platform to engineer allogeneic chimeric antigen receptor T?cell (CAR?T) candidates designed to target blood cancers and solid tumors.

The company’s core business activities encompass the discovery, development and manufacturing of off?the?shelf immunotherapies.